USG Corp (USG) 28.06 $USG USG Reports Excellent

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 12:50 PM

USG Corp (USG) 28.06 $USG

USG Reports Excellent Earnings
Illuminati Investments - at Seeking Alpha - Fri Apr 24, 5:02AM CDT

USG: 28.06 (+0.93)

Look for Shares of USG to Potentially Pullback after Yesterday's 1.50% Rise
Comtex SmarTrend(R) - Thu Apr 23, 4:37PM CDT
USG (NYSE:USG) traded in a range yesterday that spanned from a low of $26.73 to a high of $27.95. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $27.00 on volume of 6.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
USG: 28.06 (+0.93)

USG (USG) James S. Metcalf on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Apr 23, 1:27PM CDT

USG: 28.06 (+0.93)

USG (USG) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Apr 23, 7:55AM CDT

USG: 28.06 (+0.93)

USG tops Street 1Q forecasts
Automated Insights - Thu Apr 23, 7:18AM CDT
CHICAGO (AP) _ USG Corp. (USG) on Thursday reported first-quarter earnings of $24 million.
USG: 28.06 (+0.93)

USG Corporation Reports First Quarter 2015 Results
Business Wire - Thu Apr 23, 7:11AM CDT
--Business Highlights
USG: 28.06 (+0.93)

USG beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 7:02AM CDT

USG: 28.06 (+0.93)

Pre-market Equity Watch on Building Products -- Masco, Owens Corning, USG Corp., Fortune Brands Home and Security, and A.O. Smith
PR Newswire - Tue Apr 21, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
FBHS: 46.76 (+0.35), USG: 28.06 (+0.93), OC: 41.84 (+0.62), MAS: 26.19 (-0.01), AOS: 66.59 (+0.94)

USG Bullish Options Traders Make Late-Day Charge
at The Street - Mon Apr 20, 4:55AM CDT
Bullish option traders piled into USG at the end of Friday's session, ahead of the company's earnings report later this week.
USG: 28.06 (+0.93)

USG Corporation to Host First Quarter 2015 Earnings Conference Call and Webcast
Business Wire - Thu Apr 09, 8:00AM CDT
USG Corporation (NYSE:USG), a leading building products company, today announced that it will host a conference call and webcast to discuss first quarter 2015 results on Thursday, April 23, 2015, at 9:00 a.m. Eastern time (8:00 a.m. Central time).
USG: 28.06 (+0.93)

SmarTrend Watching for Potential Pullback in Shares of USG After 1.12% Gain
Comtex SmarTrend(R) - Mon Mar 23, 5:55PM CDT
USG (NYSE:USG) traded in a range yesterday that spanned from a low of $26.59 to a high of $27.00. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $26.81 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
USG: 28.06 (+0.93)

USG Corporation Turns to Tools from Fidelity to Build Its Employees' Futures
Business Wire - Mon Mar 23, 7:36AM CDT
USG Corporation (NYSE:USG), a leading building materials manufacturer, has selected Fidelity Investments to serve as the company's 401(k) plan administrator. The relationship began in the fourth quarter of 2014 and has assets under administration of approximately $745 million.
USG: 28.06 (+0.93)

Expert Briefing on Industrials Sector Stocks -- Masco, Owens Corning, USG Corp., Fortune Brands Home and Security, and MasTec
PR Newswire - Thu Mar 19, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
FBHS: 46.76 (+0.35), USG: 28.06 (+0.93), OC: 41.84 (+0.62), MAS: 26.19 (-0.01), MTZ: 17.88 (+0.13)

Trade-Ideas: USG (USG) Is Today's "Barbarian At The Gate" Stock
at The Street - Wed Mar 18, 11:36AM CDT
Trade-Ideas LLC identified USG (USG) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
USG: 28.06 (+0.93)

Downgrade Alert for USG (USG)
Comtex SmarTrend(R) - Wed Mar 18, 7:07AM CDT
USG (NYSE:USG) was downgraded from Outperform to Neutral at RW Baird today. The stock closed yesterday at $26.65 on volume of 2.1 million shares, above average daily volume of 1.9 million. USG has overhead space with shares priced $26.65, or 17.0% below the average consensus analyst price target of $32.12. USG shares should first meet resistance at the 200-day moving average (MA) of $28.40 and find additional resistance at the 50-day MA of $28.78.
USG: 28.06 (+0.93)

Warren Buffett's Top 25 Stocks for 2015
at The Street - Tue Mar 17, 9:30AM CDT
These are Warren Buffett's Top 25 stocks for 2015.
CHTR: 185.75 (+2.17), WMT: 79.84 (+0.66), MTB: 119.61 (-0.58), PCP: 200.51 (-4.65), SU: 33.06 (+0.08), V: 67.48 (-0.24), LBTYA: 52.85 (+0.47), IBM: 169.78 (-0.46), DTV: 89.85 (-0.27), DE: 88.39 (-0.20), COST: 148.12 (+0.82), BK: 42.07 (-0.51), KO: 40.89 (-0.06), AXP: 77.99 (-0.16), WFC: 54.70 (-0.16), MCO: 107.50 (-0.26), VRSN: 65.04 (-2.69), GS: 197.99 (-1.32), DVA: 83.91 (+0.50), USB: 42.74 (-0.08), USG: 28.06 (+0.93), GM: 35.59 (-0.33), PG: 81.00 (+0.05), VIAB: 70.74 (+0.04), VZ: 50.03 (-0.02)

What's in Store for Lennar (LEN) this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 10:00AM CDT
Lennar Corporation (LEN) is set to report first-quarter fiscal 2015 results on Mar 19, before the market opens.
DHI: 26.57 (+0.42), LEN: 47.19 (+0.47), RYL: 45.19 (+0.80), USG: 28.06 (+0.93)

Is One Of Warren Buffett's Portfolio Holdings A Compelling Short?
Raman Bhalla - at Seeking Alpha - Thu Mar 12, 2:19AM CDT

USG: 28.06 (+0.93), BRK.B: 142.09 (-0.34), BRK.A: 214,490.00 (-250.00)

USG Corp.: An Unjustly Cheap Housing Play
Illuminati Investments - at Seeking Alpha - Tue Mar 03, 7:56AM CST

HD: 113.70 (-0.26), USG: 28.06 (+0.93), LOW: 73.16 (-0.21), BRK.B: 142.09 (-0.34)

Insider Trading Alert - USG, CTSH And RYL Traded By Insiders
at The Street - Mon Feb 23, 9:15AM CST
Stocks with insider trader activity include USG, CTSH and RYL
RYL: 45.19 (+0.80), USG: 28.06 (+0.93), CTSH: 59.73 (-1.47)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Photocure Navigates AssureMDx's Medicare Journey

Aiming High with AssureMDx Photocure's got this bladder cancer test called AssureMDx that's at the center of its recent moves after acquiring Vesica Health a few months back. This isn't just any test; it's a urine-based, non-invasive way to snag an early look at bladder cancer. With the FDA's Breakthrough Device tag pinned on, they're not just dipping their toes in—this...

Segway Powersports Ventures into Baja 1000: Ambitions Run High

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

PharmaBlock Forum: Strategic CMC Moves Crucial for Biotech

CMC Strategies: The Unsung Hero in Biotech Development Ah, the world of biotech, where one day you're a hero in the lab, and the next you're scrambling to make sense of chemistry, manufacturing, and controls (CMC). It's high time folks started realizing that CMC isn't just procedural drudgery—it's the backbone of making a promising drug go global. That's what the...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

UAE Pioneers eATA Carnet System Beyond Europe

Breaking Tradition with Digital Innovation Well, who would’ve thought? The UAE just leapt ahead in the trade game, becoming the first to roll out the eATA Carnet system beyond the cozy confines of Europe. This isn’t some run-of-the-mill tech rollout, folks. It’s a digital revolution in how temporary imports are handled—goodbye paper, hello efficiency! With this...

Valmet Expands Board Maker Deal in Asia With New Line

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

AI Agents Redefine Finance: Deutsche & Ant Tech

AI Agents: Shaping the Future of Finance The finance world has always been about numbers and precision, but now, with the advent of AI, it’s entering a domain where machines could call the shots. Hold your horses before you imagine free-wheeling robots in suits; this is still the finance sector, where control and audits are holy grails. Deutsche Bank and Ant's Ambitious...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...